03221nam 22006372 450 991044997260332120151005020623.01-107-12231-71-280-16221-X97866101622150-511-11919-40-511-04132-20-511-15734-70-511-30447-10-511-54532-00-511-04734-7(CKB)1000000000003633(EBL)201762(OCoLC)559091674(SSID)ssj0000170343(PQKBManifestationID)11170323(PQKBTitleCode)TC0000170343(PQKBWorkID)10215372(PQKB)11649584(UkCbUP)CR9780511545320(MiAaPQ)EBC201762(Au-PeEL)EBL201762(CaPaEBR)ebr10014604(CaONFJC)MIL16221(EXLCZ)99100000000000363320090507d2002|||| uy| 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierHepatitis C virus from laboratory to clinic /Mark A. Feitelson[electronic resource]Cambridge :Cambridge University Press,2002.1 online resource (xiv, 256 pages) digital, PDF file(s)Title from publisher's bibliographic system (viewed on 05 Oct 2015).0-521-79959-7 Includes bibliographical references (p. 177-247) and index.Cover; Half-title; Title; Copyright; Dedication; Contents; Preface; Foreword; Abbreviations; Part I Basic principles; Part II Recent advances; Part III Experimental approaches; Part IV Protocols and techniques; Part V Some outstanding questions and emerging areas for investigation; References; IndexHepatitis C infects 170 million people worldwide, and has been labelled the 'silent epidemic' as a result of its concealed attack on the liver. This multidisciplinary overview covers basic concepts related to the discovery of the virus, development of serological and nucleic acid tests to detect infection, the structure of the virus genome, generation of virus gene products, and proposed replication scheme. It then goes on to introduce the epidemiology, transmission, pathogenesis of infection, the development of hepatocellular carcinoma associated with chronic virus infection, and current strategies for treatment. The book then discusses advances in cell culture systems, animal models of infection, and emerging treatments and vaccine development. Through its coverage of basic science, clinical consequences, and methods of research, this integrated and accessible account will be of immense value to biomedical scientists and clinicians alike, and a useful introduction for all those studying the virus and its effects.Hepatitis CHepatitis C virusHepatitis C.Hepatitis C virus.616.3/623Feitelson Mark1037718UkCbUPUkCbUPBOOK9910449972603321Hepatitis C virus2458849UNINA01964nam 2200337 450 991071432160332120230814161626.0(CKB)4100000008043649(NjHacI)994100000008043649(EXLCZ)99410000000804364920230806d2019 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierThe Emoluments Clauses of the U.S. Constitution (IF11086) /Kevin J. Hickey, Michael A. FosterWashington, D.C. :Congressional Research Service,2019.1 online resourceLitigation during the Trump Administration raised a The purpose of the Ineligibility Clause is to preserve the number of legal issues concerning formerly obscure separation of powers and prevent executive influence on the constitutional provisions that prohibit the acceptance or legislature (and vice versa). The Clause thus prohibits receipt of "emoluments" in certain circumstances. This In federal officers from simultaneously serving as Members of Focus provides an overview of these constitutional Congress. Moreover, a Member of Congress may not hold provisions, highlighting several unsettled legal areas an office if it was established during his tenure or if the concerning their meaning and scope, and reviewing the emoluments of that office were increased during his tenure. litigation against former President Donald Trump based on Officers Subject to the his alleged violations of the Emoluments Clauses.ConstitutionsUnited StatesConstitutions342.73023Hickey Kevin J.1379331Foster Michael A(Legislative attorney)NjHacINjHaclBOOK9910714321603321The Emoluments Clauses of the U.S. Constitution (IF11086)3418767UNINA